<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83915">
  <stage>Registered</stage>
  <submitdate>12/05/2009</submitdate>
  <approvaldate>29/05/2009</approvaldate>
  <actrnumber>ACTRN12609000382279</actrnumber>
  <trial_identification>
    <studytitle>Regulation of blood fat transport following a fatty test meal in lean men and men with the metabolic syndrome</studytitle>
    <scientifictitle>Novel studies of postparandial lipoprotein metabolism in lean men and men with the metabolic syndrome</scientifictitle>
    <utrn />
    <trialacronym>4P</trialacronym>
    <secondaryid>EC2009/014 Royal Perth Hospital Ethics Committee</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metabolic syndrome and healthy lean control subjects</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Observational study. Imediately following a high fat test meal, intravenous D3-leucine stable isotope and two oral vitamin A capsules (50,000U each) will be used as kinetic tracers of lipoprotein metabolism. This wil be given only once and on one day only.</interventions>
    <comparator>Age matched lean healty control subjects.
15 age-matched normolipidaemic men with a body mass index (BMI) &lt;25kg/m2, waist circumference &lt;102cm, triglycerides &lt;1.0mmol/L, high density lipoprotein (HDL)-cholesterol =1.2 mmol/L, will also be recruited. All outcome measures will be compared with the metabolic syndrome groups.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Area under the curve (AUC) for triglycerides will be used as an assessment tool for triglyceride metabolism. Plasma will be taken at all time points (baseline, 5, 10, 20, 30, 40, 60mins, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 24, 48, 72, 96 hours) and AUC for triglycerides will be determined and compared between groups. All analyses will be carried out using SPSS (SPSS, Inc., Chicago, USA). Group characteristics will be compared by t-tests and general linear modelling after logarithmmic transformation of skewed variables where appropriate.  Associations will be examined by simple and multivariate linear regression method.  Compartmental analysis will be used to develop and fit models to lipid and lipoprotein tracer data.</outcome>
      <timepoint>AUC time points are baseline, 5, 10, 20, 30, 40, 60mins, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 24, 48, 72, 96 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>AUC for vitamin A will be used as an assessment tool for triglyceride concentrations. Plasma will be taken at all time points (baseline, 5, 10, 20, 30, 40, 60mins, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 24, 48, 72, 96 hours) and AUC for vitamin A will be determined and compared between groups. All analyses will be carried out using SPSS (SPSS, Inc., Chicago, USA). Group characteristics will be compared by t-tests and general linear modelling after logarithmmic transformation of skewed variables where appropriate.  Associations will be examined by simple and multivariate linear regression method.  Compartmental analysis will be used to develop and fit models to lipid and lipoprotein tracer data.</outcome>
      <timepoint>AUC time points are baseline, 5, 10, 20, 30, 40, 60mins, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 24, 48, 72, 96 hours</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All men will be aged 20-75yr and be non-smoking. 30 metabolic syndrome (MetS) men with a body mass index (BMI) &lt;40kg/m will be recruited.  The metabolic syndrome (MetS) will be defined by National Cholesterol Education Programme (NCEP) criteria as the presence of at least three of the following:  waist circumference &gt;102cm, triglycerides &gt;1.7mmol/L, high densily lipoprotein (HDL)-cholesterol &lt;1.05mmol/L, blood pressure &gt;130/&gt;85mm, and fasting glucose &gt;6.1mmol/L.  The 15 metabolic syndrome (MetS) men treated with Crestor will have a low density lipoprotein (LDL)-cholesterol &lt;2.5mmol/L. 
15 age-matched normolipidaemic men with a body mass index (BMI) &lt;25kg/m2, waist circumference &lt;102cm, triglycerides &lt;1.0mmol/L, high density lipoprotein (HDL)-cholesterol =1.2 mmol/L, will also be recruited.</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Subjects with plasma LDL-cholesterol &gt;5mmo/L, diabetes mellitus, genetic hyperlipidaemia (e.g. familial hypercholesterolaemia (FH), consumption of &gt;30g alcohol/day, apolipoprotein E2/E2 genotype, macroproteinuria, creatinaemia (&gt;120?mol/L), hypothyroidism, and hepatic dysfunction (aspartate transaminase (AST) or alanine transaminase (ALT) &gt;2x upper limit of normal (ULN), Creatine kinase &gt;3x upper limit of normal (ULN) in Crestor treated subjects, major systemic illness and use of steroids or other agents that may influence lipid metabolism, cardiovascular event within past 6 months, subjects on hypocaloric diets, lactose intolerance or intolerance to cream or eggs, anaemia;  any significant illness that in the opinion of reviewing physician would bear on the study (e.g. heart murmur or psychiatric conditions)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Case control</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>45</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Gerald Watts</primarysponsorname>
    <primarysponsoraddress>School of Medicine and Pharmacology, Royal Perth Hospital, Rear 50 Murray Street, PO Box X2213, Perth, WA 6847</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC) grant, Universtiy of Western Australia</fundingname>
      <fundingaddress>35 Stirling Highway, Crawley, Perth, WA 6009</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Hugh Barrett</othercollaboratorname>
      <othercollaboratoraddress>School of Medicine and Pharmacology, Royal Perth Hospital, Rear 50 Murray Street, PO Box X2213, Perth, WA 6847</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim is to carry out a case-control study to demonstrate abnormalities in postprandial lipoprotein metabolism, in men with the metabolic syndrome (MetS) compared with lean men.  A further aim is to demonstrate that postprandial lipoprotein metabolism is improved, but not normalized, in men with MetS treated with a statin.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Ethics Commitee</ethicname>
      <ethicaddress>Royal Perth Hospital, Rear 50 Murray Street, PO Box X2213, Perth, WA 6847</ethicaddress>
      <ethicapprovaldate>3/03/2009</ethicapprovaldate>
      <hrec>EC2009/014</hrec>
      <ethicsubmitdate>3/02/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof Hugh Barrett</name>
      <address>School of Medicine and Pharmacology, Royal Perth Hospital, Rear 50 Murray Street, PO Box X2213, Perth, WA 6847</address>
      <phone>+ 61 8 9224 0249</phone>
      <fax>+61 8 9224 0246</fax>
      <email>hugh.barrett@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sandra Hamilton</name>
      <address>School of Medicine and Pharmacology, Royal Perth Hospital, Rear 50 Murray Street, PO Box X2213, Perth, WA 6847</address>
      <phone>+61 8 9224 0318</phone>
      <fax>+61 8 9224 0243</fax>
      <email>sandy.hamilton@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sandra Hamilton</name>
      <address>School of Medicine and Pharmacology, Royal Perth Hospital, Rear 50 Murray Street, PO Box X2213, Perth, WA 6847</address>
      <phone>+61 8 9224 0318</phone>
      <fax>+ 61 8 9224 0243</fax>
      <email>sandy.hamilton@uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>